

PharmLabs San Diego Certificate of Analysis



3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-000098-LIC
 ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368

Sample **D9 Syrup - Grape**

| | | | |
|--------------------------------|--|-----------------------|------|
| Sample ID SD230803-014 (82009) | Matrix Edible/Tincture (Other Cannabis Good) | Address | Name |
| Distributor License 12345678 | | Reported Aug 03, 2023 | |
| Sampled - | Received Aug 02, 2023 | | |
| Analyses executed CANX | | Density (g/mL) 1.37 | |

CANX - Cannabinoids Analysis

Analyzed Aug 03, 2023 | Instrument HPLC-VWD | Method
 The expanded Uncertainty of the Cannabinoid analysis is approximately ±7.806% at the 95% Confidence Level

| Analyte | LOD mg/g | LOQ mg/g | Result % | Result mg/g |
|--|----------|----------|----------|-------------|
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV) | 0.013 | 0.041 | ND | ND |
| Cannabidiol (CBDO) | 0.002 | 0.007 | ND | ND |
| Abnormal Cannabidiol (α-CBDO) | 0.01 | 0.031 | ND | ND |
| (+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC) | 0.012 | 0.036 | ND | ND |
| 11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC) | 0.007 | 0.021 | ND | ND |
| Cannabidiolic Acid (CBDA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol Acid (CBGA) | 0.001 | 0.16 | ND | ND |
| Cannabigerol (CBG) | 0.001 | 0.16 | ND | ND |
| Cannabidiol (CBD) | 0.001 | 0.16 | ND | ND |
| 1(S)-THD (s-THD) | 0.013 | 0.041 | ND | ND |
| 1(R)-THD (r-THD) | 0.025 | 0.075 | ND | ND |
| Tetrahydrocannabinol (THCV) | 0.001 | 0.16 | ND | ND |
| Δ8-tetrahydrocannabinol (Δ8-THCV) | 0.021 | 0.064 | ND | ND |
| Cannabidiol (CBDH) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THCB) | 0.013 | 0.038 | ND | ND |
| Cannabinol (CBN) | 0.001 | 0.16 | ND | ND |
| Cannabiphorol (CBDP) | 0.015 | 0.047 | ND | ND |
| exo-THC (exo-THC) | 0.005 | 0.16 | ND | ND |
| Tetrahydrocannabinol (Δ9-THC) | 0.003 | 0.16 | 0.10 | 1.10 |
| Δ8-tetrahydrocannabinol (Δ8-THC) | 0.004 | 0.16 | ND | ND |
| (6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10) | 0.015 | 0.16 | ND | ND |
| Hexahydrocannabinol (S Isomer) (9s-HHC) | 0.017 | 0.16 | ND | ND |
| (6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10) | 0.007 | 0.16 | ND | ND |
| Hexahydrocannabinol (R Isomer) (9r-HHC) | 0.016 | 0.16 | ND | ND |
| Tetrahydrocannabinolic Acid (THCA) | 0.001 | 0.16 | ND | ND |
| Δ9-Tetrahydrocannabinol (Δ9-THCH) | 0.024 | 0.071 | ND | ND |
| Cannabinol Acetate (CBNO) | 0.014 | 0.043 | ND | ND |
| Δ9-Tetrahydrocannabinol (Δ9-THCP) | 0.017 | 0.16 | ND | ND |
| Δ8-Tetrahydrocannabinol (Δ8-THCP) | 0.041 | 0.16 | ND | ND |
| Cannabicitran (CBT) | 0.005 | 0.16 | ND | ND |
| Δ8-THC-O-acetate (Δ8-THCO) | 0.076 | 0.16 | ND | ND |
| 9(S)-HHCP (s-HHCP) | 0.031 | 0.094 | ND | ND |
| Δ9-THC-O-acetate (Δ9-THCO) | 0.066 | 0.16 | ND | ND |
| 9(R)-HHCP (r-HHCP) | 0.026 | 0.079 | ND | ND |
| 9(S)-HHC-O-acetate (s-HHCO) | 0.005 | 0.16 | ND | ND |
| 9(R)-HHC-O-acetate (r-HHCO) | 0.008 | 0.025 | ND | ND |
| 3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8) | 0.067 | 0.204 | ND | ND |
| Δ9-THC methyl ether (Δ9-MeO-THC) | | | NT | NT |
| Total THC (THCa * 0.877 + Δ9THC) | | | 0.10 | 1.10 |
| Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC) | | | 0.10 | 1.10 |
| Total CBD (CBDA * 0.877 + CBD) | | | ND | ND |
| Total CBG (CBGA * 0.877 + CBG) | | | ND | ND |
| Total HHC (9r-HHC + 9s-HHC) | | | ND | ND |
| Total Cannabinoids | | | 0.10 | 1.10 |

Sample photography



UI Unidentified
 ND Not Detected
 N/A Not Applicable
 NT Not Reported
 LOD Limit of Detection
 LOQ Limit of Quantification
 <LOQ Detected
 >ULOL Above upper limit of linearity
 CFU/g Colony Forming Units per 1 gram
 TNTC Too Numerous to Count



Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager
 Thu, 03 Aug 2023 13:50:45 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Certification L17-427-1

*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.

